438 related articles for article (PubMed ID: 33219109)
1. Prognostic significance of natriuretic peptide levels in atrial fibrillation without heart failure.
Hamatani Y; Iguchi M; Ueno K; Aono Y; Esato M; Tsuji H; Wada H; Hasegawa K; Ogawa H; Abe M; Morita S; Akao M
Heart; 2021 May; 107(9):705-712. PubMed ID: 33219109
[TBL] [Abstract][Full Text] [Related]
2. Comparison of BNP and NT-proBNP in Patients With Heart Failure and Reduced Ejection Fraction.
Rørth R; Jhund PS; Yilmaz MB; Kristensen SL; Welsh P; Desai AS; Køber L; Prescott MF; Rouleau JL; Solomon SD; Swedberg K; Zile MR; Packer M; McMurray JJV
Circ Heart Fail; 2020 Feb; 13(2):e006541. PubMed ID: 32065760
[TBL] [Abstract][Full Text] [Related]
3. Prognostic Value of N-Terminal Pro-B-Type Natriuretic Peptide Levels in Heart Failure Patients With and Without Atrial Fibrillation.
Kristensen SL; Jhund PS; Mogensen UM; Rørth R; Abraham WT; Desai A; Dickstein K; Rouleau JL; Zile MR; Swedberg K; Packer M; Solomon SD; Køber L; McMurray JJV;
Circ Heart Fail; 2017 Oct; 10(10):. PubMed ID: 29018174
[TBL] [Abstract][Full Text] [Related]
4. N-Terminal Pro-B-Type Natriuretic Peptide Levels for Risk Prediction in Patients With Heart Failure and Preserved Ejection Fraction According to Atrial Fibrillation Status.
Kristensen SL; Mogensen UM; Jhund PS; Rørth R; Anand IS; Carson PE; Desai AS; Pitt B; Pfeffer MA; Solomon SD; Zile MR; Køber L; McMurray JJV
Circ Heart Fail; 2019 Mar; 12(3):e005766. PubMed ID: 30871349
[TBL] [Abstract][Full Text] [Related]
5. Influence of atrial fibrillation on plasma von willebrand factor, soluble E-selectin, and N-terminal pro B-type natriuretic peptide levels in systolic heart failure.
Freestone B; Gustafsson F; Chong AY; Corell P; Kistorp C; Hildebrandt P; Lip GY
Chest; 2008 May; 133(5):1203-8. PubMed ID: 18339785
[TBL] [Abstract][Full Text] [Related]
6. Prognostic Value of Serum N-Terminal Pro-Brain Natriuretic Peptide Level over Heart Failure for Stroke Events and Deaths in Patients with Atrial Fibrillation.
Kuronuma K; Okumura Y; Morikawa T; Yokoyama K; Matsumoto N; Tachibana E; Oiwa K; Matsumoto M; Kojima T; Haruta H; Nomoto K; Sonoda K; Arima K; Kogawa R; Takahashi F; Kotani T; Ohkubo K; Fukushima S; Itou S; Kondo K; Chiku M; Ohno Y; Onikura M; Hirayama A;
Int Heart J; 2020 May; 61(3):492-502. PubMed ID: 32418966
[TBL] [Abstract][Full Text] [Related]
7. Usefulness of N-terminal pro-B-type natriuretic Peptide levels for stroke risk prediction in anticoagulated patients with atrial fibrillation.
Roldán V; Vílchez JA; Manzano-Fernández S; Jover E; Gálvez J; Puche CM; Valdés M; Vicente V; Lip GY; Marín F
Stroke; 2014 Mar; 45(3):696-701. PubMed ID: 24519407
[TBL] [Abstract][Full Text] [Related]
8. [Changes in NT-proBNP levels in patients with atrial fibrillation related to heart failure].
Pokorná V; Jurkovicová O; Kaluzay J; Stecová A; Pont'uch P
Vnitr Lek; 2010 Aug; 56(8):788-94. PubMed ID: 20845610
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and Safety of Dapagliflozin in Heart Failure With Reduced Ejection Fraction According to N-Terminal Pro-B-Type Natriuretic Peptide: Insights From the DAPA-HF Trial.
Butt JH; Adamson C; Docherty KF; de Boer RA; Petrie MC; Inzucchi SE; Kosiborod MN; Maria Langkilde A; Lindholm D; Martinez FA; Bengtsson O; Schou M; O'Meara E; Ponikowski P; Sabatine MS; Sjöstrand M; Solomon SD; Jhund PS; McMurray JJV; Køber L
Circ Heart Fail; 2021 Dec; 14(12):e008837. PubMed ID: 34802253
[TBL] [Abstract][Full Text] [Related]
10. N-terminal pro-B-type natriuretic peptide for risk assessment in patients with atrial fibrillation: insights from the ARISTOTLE Trial (Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation).
Hijazi Z; Wallentin L; Siegbahn A; Andersson U; Christersson C; Ezekowitz J; Gersh BJ; Hanna M; Hohnloser S; Horowitz J; Huber K; Hylek EM; Lopes RD; McMurray JJ; Granger CB
J Am Coll Cardiol; 2013 Jun; 61(22):2274-84. PubMed ID: 23563134
[TBL] [Abstract][Full Text] [Related]
11. Differential Associations of A-/B-Type Natriuretic Peptides With Cardiac Structure, Function, and Prognosis in Heart Failure.
Tan ESJ; Chan SP; Liew OW; Chong JPC; Gerard Leong KT; Daniel Yeo PS; Ong HY; Jaufeerally F; Sim D; Ling LH; Lam CSP; Richards AM
JACC Heart Fail; 2024 Mar; 12(3):461-474. PubMed ID: 37897459
[TBL] [Abstract][Full Text] [Related]
12. Natriuretic peptide plasma concentrations and risk of cardiovascular versus non-cardiovascular events in heart failure with reduced ejection fraction: Insights from the PARADIGM-HF and ATMOSPHERE trials.
Khan MS; Kristensen SL; Vaduganathan M; Kober L; Abraham WT; Desai AS; Solomon SD; Swedberg K; Dickstein K; Zile MR; Packer M; McMurray JJ; Butler J
Am Heart J; 2021 Jul; 237():45-53. PubMed ID: 33621540
[TBL] [Abstract][Full Text] [Related]
13. Associations With and Prognostic and Discriminatory Role of N-Terminal Pro-B-Type Natriuretic Peptide in Heart Failure With Preserved Versus Mid-range Versus Reduced Ejection Fraction.
Savarese G; Orsini N; Hage C; Dahlström U; Vedin O; Rosano GMC; Lund LH
J Card Fail; 2018 Jun; 24(6):365-374. PubMed ID: 29597053
[TBL] [Abstract][Full Text] [Related]
14. Atrial fibrillation and amino-terminal pro-brain natriuretic peptide as independent predictors of prognosis in systolic heart failure.
Dini FL; Gabutti A; Passino C; Fontanive P; Emdin M; De Tommasi SM
Int J Cardiol; 2010 Apr; 140(3):344-50. PubMed ID: 19128846
[TBL] [Abstract][Full Text] [Related]
15. [Prognostic value of N-terminal B-type natriuretic peptide on all-cause mortality in heart failure patients with preserved ejection fraction].
Cao J; Jin XJ; Zhou J; Chen ZY; Xu DL; Yang XC; Dong W; Li LW; Luo J; Chen L; Fu M; Zhou JM; Ge JB
Zhonghua Xin Xue Guan Bing Za Zhi; 2019 Nov; 47(11):875-881. PubMed ID: 31744276
[No Abstract] [Full Text] [Related]
16. Clinical and prognostic effects of atrial fibrillation in heart failure patients with reduced and preserved left ventricular ejection fraction.
Linssen GC; Rienstra M; Jaarsma T; Voors AA; van Gelder IC; Hillege HL; van Veldhuisen DJ
Eur J Heart Fail; 2011 Oct; 13(10):1111-20. PubMed ID: 21642293
[TBL] [Abstract][Full Text] [Related]
17. Effect of atrial fibrillation on plasma NT-proBNP in chronic heart failure.
Corell P; Gustafsson F; Kistorp C; Madsen LH; Schou M; Hildebrandt P
Int J Cardiol; 2007 May; 117(3):395-402. PubMed ID: 16919342
[TBL] [Abstract][Full Text] [Related]
18. N-terminal pro brain natriuretic peptide eliminates the prognostic effect of atrial fibrillation in patients with chronic heart failure.
Schnorbach J; Fröhlich H; Täger T; Corletto A; Katus HA; Frankenstein L
ESC Heart Fail; 2019 Aug; 6(4):640-648. PubMed ID: 31259484
[TBL] [Abstract][Full Text] [Related]
19. NT-proBNP as a marker for atrial fibrillation and heart failure in four observational outpatient trials.
Werhahn SM; Becker C; Mende M; Haarmann H; Nolte K; Laufs U; Zeynalova S; Löffler M; Dagres N; Husser D; Dörr M; Gross S; Felix SB; Petersmann A; Herrmann-Lingen C; Binder L; Scherer M; Hasenfuß G; Pieske B; Edelmann F; Wachter R
ESC Heart Fail; 2022 Feb; 9(1):100-109. PubMed ID: 34850596
[TBL] [Abstract][Full Text] [Related]
20. Atrial fibrillation is an independent determinant of increased NT-proBNP levels in outpatients with signs and symptoms of heart failure.
Jug B; Sebestjen M; Sabovic M; Pohar M; Keber I
Wien Klin Wochenschr; 2009; 121(21-22):700-6. PubMed ID: 19998011
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
